An exploratory research on the influence of amyloid deposit (measured with (18F)flutemetamol) on disconnection in the core episodic network” and between regions involved in anosognosia for memory impairment

Phase 1

• Conditions: Alzheimer's disease (mild, moderate and moderately severe stage) and control population; Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

• Registration Number: EUCTR2012-004462-18-BE
• Lead Sponsor: Service of Neurology CHU Liege

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-09
• Last Update Posted: 26 September 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Control population without major disease and with normal cognition.
Alzheimer's disease diagnosed according to international criteria.
Age between 50 and 90 y
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

Exclusion criteria will be systemic disease, cancer, associated vascular dementia. Exclusion criteria for MRI will be taken into account.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified